Tandis Vazin

Tandis Vazin, PhD, is a seasoned professional in the field of gene therapy and regenerative medicine, currently serving as Senior Scientific Advisor and Chief Scientific Officer at Acrigen Biosciences since September 2019. Vazin has a robust track record, including generating proof of concept for innovative technologies, managing discovery platforms, and contributing to patent applications. Previous roles include Corporate Advisor at CNS Gene Therapy NewCo, where the establishment of a CNS gene therapy company was spearheaded, and Preclinical and Strategy Consultant at Juvena Therapeutics, supporting therapeutic development and fundraising efforts. Vazin has also held leadership positions at Ambys Medicines and 4D Molecular Therapeutics, with a focus on AAV variant development and gene therapy applications. An academic background includes a PhD in Neuroscience from NIH/Johns Hopkins University and experience as a Senior Scientist at UC Berkeley. Vazin's contributions to the scientific community are underscored by numerous innovations and advancements in gene editing and stem cell biology.